H.C. Wainwright analyst Ananda Ghosh has maintained their bullish stance on MAZE stock, giving a Buy rating on August 14.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ananda Ghosh’s rating is based on the promising potential of Maze Therapeutics’ MZE782 program in treating chronic kidney disease (CKD). The analyst highlights the significance of the Phase 1 trial data, which is expected to be shared in the third quarter of 2025, and emphasizes the importance of solute transporters like SLC6A19 in CKD. The discussions with key opinion leaders (KOLs) and an extensive literature review reinforce the biological and clinical rationale for MZE782’s mechanism of action, particularly its strategy of inhibiting SLC6A19 in both PKU and CKD.
Additionally, Ghosh notes that the accumulation of certain amino acids correlates with decreased renal function, validating MZE782’s approach. The analyst also points out the potential for MZE782 to meaningfully alter CKD outcomes if robust target engagement is shown in the Phase 1 study. The consensus among KOLs is that significant increases in urinary biomarkers would support further trials, and the regulatory precedent requires new therapies to demonstrate superiority over standard care. These factors collectively deepen confidence in the safety and potential disease-modifying effects of SLC6A19 inhibition, making the CKD indication a viable target for earlier proof-of-concept investment.
In another report released on August 14, J.P. Morgan also maintained a Buy rating on the stock with a $27.00 price target.